Adenosine A1 and A2 receptors are widely distributed in the brain and spinal cord and represent a non-opiate target for pain management. Activated spinal A1 receptors inhibit sensory transmission by inhibiting the slow ventral root potential, which is the C-fiber-evoked excitatory response associated with nociception. Adenosine may inhibit intrinsic neurons through an increase in K+ conductance and presynaptic inhibition of sensory nerve terminals to inhibit the release of substance P and perhaps glutamate. Although adenosine A3 receptors are not found in the nervous system, adenosine is also known to have anti-inflammatory properties that may contribute to pain relief in the peripheral setting of inflammation.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
160
University of California, San Francisco
San Francisco, California, United States
University of Miami/Miller School of Medicine
Miami, Florida, United States
Medical College of Georgia
Augusta, Georgia, United States
University of Chicago
Chicago, Illinois, United States
Duke University Medical Center
Durham, North Carolina, United States
Wake Forest University/Forsyth Medical Center
Winston-Salem, North Carolina, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Memorial Hermann-Memorial City Hospital
Houston, Texas, United States
Dose-response
efficacy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.